Recombinant Human TNFSF1 protein

Tumor necrosis factor superfamily member 1 (TNFSF1), also known as lymphotoxin-alpha (LT-α), is a cytokine belonging to the TNF superfamily, first identified in the 1960s for its antitumor activity. It exists in both soluble homotrimeric (LT-α3) and membrane-bound heterotrimeric (LT-α1β2) forms, interacting with receptors such as TNFRSF1A, TNFRSF1B, and HVEM to regulate immune responses. TNFSF1 is primarily produced by activated lymphocytes and plays critical roles in lymphoid organ development, immune cell communication, and inflammatory responses. It activates NF-κB and MAPK signaling pathways, influencing processes like apoptosis, cell proliferation, and pathogen defense. Dysregulation of TNFSF1 is linked to autoimmune diseases (e.g., rheumatoid arthritis), chronic inflammation, and cancer.

Recombinant TNFSF1 protein is engineered using expression systems (e.g., E. coli, mammalian cells) to produce bioactive forms for research and therapeutic applications. It retains functional epitopes, enabling studies on receptor interactions, signaling mechanisms, and immune modulation. In drug development, TNFSF1 serves as a tool for screening inhibitors or agonists targeting TNF-related pathways. Its therapeutic potential is explored in cancer immunotherapy and autoimmune disorders, though challenges include managing systemic toxicity and optimizing delivery. As a research reagent, recombinant TNFSF1 aids in elucidating its dual role in promoting inflammation and maintaining immune homeostasis, offering insights into disease mechanisms and targeted interventions.